SR147778 [5-(4-Bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a New Potent and Selective Antagonist of the CB1 Cannabinoid Receptor: Biochemical and Pharmacological Characterization

Based on binding, functional, and pharmacological data, this study introduces SR147778 [5-(4-bromophenyl)-1-(2,4-dichloro-phenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide] as a highly potent, selective, and orally active antagonist for the CB1 receptor. This compound displays nanomolar affinity (Ki = 0.56 and 3.5 nM) for both the rat brain and human CB1 recombinant receptors, respectively. It has low affinity (Ki = 400 nM) for both the rat spleen and human CB2 receptors. Furthermore, it shows no affinity for any of the over 100 targets investigated (IC50 > 1 μM). In vitro, SR147778 antagonizes the inhibitory effects of CP 55,940 [(1R,3R,4R)-3-[2-hydroxy-4-(1,1-dimethylheptyl)phenyl]-4-(3-hydroxypropyl)cyclohexan-1-ol] on both the mouse vas deferens contractions (pA2 value = 8.1) and on forskolin-stimulated adenylyl cyclase activity in the U373 MG cell lines (pA2 value = 8.2) but not in Chinese hamster ovary (CHO) cells permanently expressing the human peripheral cannabinoid receptor (hCB2). SR147778 is able to block the mitogen-activated protein kinase activity induced by CP 55,940 in the CHO cell line expressing human brain cannabinoid receptor (IC50 = 9.6 nM) but was inactive in cells expressing hCB2. After oral administration, SR147778 displaced the ex vivo [3H]-CP 55,940 binding to mouse brain membranes (ED50 = 3.8 mg/kg) with a long duration of action, whereas it did not interact with the CB2 receptor expressed in the mouse spleen. Using different routes of administration, SR147778 (0.3–3 mg/kg) is shown to antagonize pharmacological effects (hypothermia, analgesia, and gastrointestinal transit) induced by R-(+)-(2,3-dihydro-5-methyl-3-[{4-morpholinyl}methyl] pyrol [1,2,3-de]-1,4-benzoxazin-6-yl)(1-naphthalenyl) methanone in mice. Finally, per se, SR147778 (0.3–10 mg/kg) is able to reduce ethanol or sucrose consumption in mice and rats and food intake in fasted and nondeprived rats.

[1]  A. Lichtman,et al.  Δ9-Tetrahydrocannabinol impairs spatial memory through a cannabinoid receptor mechanism , 1996, Psychopharmacology.

[2]  G. Wenger,et al.  Effects of drugs of abuse on acquisition of behavioral chains in squirrel monkeys , 2005, Psychopharmacology.

[3]  D. Lovinger,et al.  G Protein-coupled Endothelial Receptor for Atypical Cannabinoid Ligands Modulates a Ca2+-dependent K+ Current* , 2003, Journal of Biological Chemistry.

[4]  F. Drago,et al.  Amnesia induced by beta-amyloid fragments is counteracted by cannabinoid CB1 receptor blockade. , 2003, European journal of pharmacology.

[5]  J. Leander,et al.  SR141716A, a cannabinoid CB1 receptor antagonist, improves memory in a delayed radial maze task. , 2003, European journal of pharmacology.

[6]  D. Cota,et al.  Endogenous cannabinoid system as a modulator of food intake , 2003, International Journal of Obesity.

[7]  K. Mackie,et al.  Nonpsychotropic Cannabinoid Receptors Regulate Microglial Cell Migration , 2003, The Journal of Neuroscience.

[8]  G. Perrault,et al.  SR141716, a central cannabinoid (CB1) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats , 2002, Behavioural pharmacology.

[9]  G. Gessa,et al.  Blockade by the cannabinoid CB1 receptor antagonist, SR 141716, of alcohol deprivation effect in alcohol-preferring rats , 2002 .

[10]  R. Capasso,et al.  Endocannabinoids and the gut. , 2002, Prostaglandins, leukotrienes, and essential fatty acids.

[11]  B. Basavarajappa,et al.  Neuromodulatory role of the endocannabinoid signaling system in alcoholism: an overview. , 2002, Prostaglandins, leukotrienes, and essential fatty acids.

[12]  J. Samochowiec,et al.  Association of a CB1 cannabinoid receptor gene (CNR1) polymorphism with severe alcohol dependence. , 2002, Drug and alcohol dependence.

[13]  C. Breivogel,et al.  Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. , 2001, Molecular pharmacology.

[14]  T. Bonner,et al.  Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[15]  E. Gardner,et al.  Cannabinoid Transmission and Reward-Related Events , 1998, Neurobiology of Disease.

[16]  J. Simiand,et al.  SR 141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. , 1998, Behavioural pharmacology.

[17]  G. Gessa,et al.  Cannabinoid modulation of intestinal propulsion in mice. , 1998, European journal of pharmacology.

[18]  P. Casellas,et al.  A Selective Inverse Agonist for Central Cannabinoid Receptor Inhibits Mitogen-activated Protein Kinase Activation Stimulated by Insulin or Insulin-like Growth Factor 1 , 1997, The Journal of Biological Chemistry.

[19]  P. Soubrié,et al.  Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors , 1997, Psychopharmacology.

[20]  P. Ferrara,et al.  Molecular cloning, expression and function of the murine CB2 peripheral cannabinoid receptor. , 1996, Biochimica et biophysica acta.

[21]  P. Casellas,et al.  Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. , 1995, The Biochemical journal.

[22]  S. Galiègue,et al.  Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. , 1995, European journal of biochemistry.

[23]  Z. Vogel,et al.  Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. , 1995, Biochemical pharmacology.

[24]  P. Casellas,et al.  Stimulation of Cannabinoid Receptor CB1 Induces krox-24 Expression in Human Astrocytoma Cells (*) , 1995, The Journal of Biological Chemistry.

[25]  P. Soubrié,et al.  Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist. , 1995, Life sciences.

[26]  M. Kaghad,et al.  An Amino-terminal Variant of the Central Cannabinoid Receptor Resulting from Alternative Splicing (*) , 1995, The Journal of Biological Chemistry.

[27]  M. Herkenham,et al.  Cannabinoid receptor binding and messenger RNA expression in human brain: An in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer's brains , 1994, Neuroscience.

[28]  P. Soubrié,et al.  SR141716A, a potent and selective antagonist of the brain cannabinoid receptor , 1994, FEBS letters.

[29]  E. Van Obberghen,et al.  Cyclic AMP activates the mitogen-activated protein kinase cascade in PC12 cells. , 1994, The Journal of biological chemistry.

[30]  S. Munro,et al.  Molecular characterization of a peripheral receptor for cannabinoids , 1993, Nature.

[31]  P. Casellas,et al.  Cannabinoid-receptor expression in human leukocytes. , 1993, European journal of biochemistry.

[32]  D. Gibson,et al.  Isolation and structure of a brain constituent that binds to the cannabinoid receptor. , 1992, Science.

[33]  G Vassart,et al.  Molecular cloning of a human cannabinoid receptor which is also expressed in testis. , 1991, The Biochemical journal.

[34]  T. Bonner,et al.  Structure of a cannabinoid receptor and functional expression of the cloned cDNA , 1990, Nature.

[35]  A. Howlett,et al.  Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma cell membranes. , 1984, Molecular pharmacology.

[36]  E. Abel Cannabis: effects on hunger and thirst. , 1975, Behavioral biology.

[37]  J. Deutsch Behavioral maintenance of high concentrations of blood ethanol and physical dependence in the rat. , 1973, Science.